Ψ-DODFMO
| Clinical data | |
|---|---|
| Other names | 4-Difluoromethoxy-2,6-dimethoxyamphetamine |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ~20 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C12H17F2NO3 |
| Molar mass | 261.269 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ψ-DODFMO, also known as 4-difluoromethoxy-2,6-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and ψ-phenethylamine families. It is the amphetamine (α-methyl) analogue of ψ-2C-DFMO and is also structurally related to other psychedelics like difluoromescaline (DFM) and 2C-T-35 (2C-T-DFM). The drug has been found to be active at a dose of 5 mg plus 5 mg (or 10 mg total) orally, with moderately intense effects and a relatively long duration of around 20 hours. Ψ-DODFMO was first described in the scientific literature by Daniel Trachsel in 2012. It is a controlled substance in Canada under phenethylamine blanket-ban language.